BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 46.0
(-2.17%)
JPY 46.0
(-2.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 112.5 Million JPY | 0.0% |
| 2022 | - JPY | -100.0% |
| 2021 | 87.5 Million JPY | 0.0% |
| 2020 | - JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| 2016 | - JPY | 0.0% |
| 2015 | - JPY | 0.0% |
| 2014 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - JPY | -100.0% |
| 2023 Q3 | 500 Million JPY | 0.0% |
| 2023 FY | 112.5 Million JPY | 0.0% |
| 2023 Q4 | 112.5 Million JPY | -77.5% |
| 2023 Q1 | - JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2022 Q4 | - JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q1 | - JPY | -100.0% |
| 2022 FY | - JPY | -100.0% |
| 2021 Q1 | - JPY | 0.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 FY | 87.5 Million JPY | 0.0% |
| 2021 Q4 | 87.5 Million JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q4 | - JPY | 0.0% |
| 2020 FY | - JPY | 0.0% |
| 2020 Q1 | - JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | - JPY | 0.0% |
| 2019 Q1 | - JPY | 0.0% |
| 2019 Q4 | - JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 Q1 | - JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q4 | - JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2017 Q4 | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| 2017 Q1 | - JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2016 Q2 | - JPY | 0.0% |
| 2016 Q1 | - JPY | 0.0% |
| 2016 FY | - JPY | 0.0% |
| 2016 Q4 | - JPY | 0.0% |
| 2016 Q3 | - JPY | 0.0% |
| 2015 Q4 | - JPY | 0.0% |
| 2015 Q3 | - JPY | 0.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 FY | - JPY | 0.0% |
| 2014 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 95.445% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 96.959% |
| Linical Co., Ltd. | 3 Billion JPY | 96.252% |
| Trans Genic Inc. | 2.25 Billion JPY | 95.016% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -4776.463% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 95.449% |
| AnGes, Inc. | 362.67 Million JPY | 68.98% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -5.289% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 99.848% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | 52.327% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 89.855% |
| Carna Biosciences, Inc. | 182.97 Million JPY | 38.515% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 87.29% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 69.406% |
| Chiome Bioscience Inc. | 291 Million JPY | 61.34% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 95.631% |
| PeptiDream Inc. | 22.79 Billion JPY | 99.507% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | 64.305% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | 83.083% |
| Healios K.K. | 4.53 Billion JPY | 97.518% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | 21.248% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -15.335% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 87.946% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 88.378% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 84.46% |
| StemCell Institute Inc. | 8.78 Million JPY | -1180.738% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | 25.62% |